By Robert L. Avery MD; and Allen C. Ho, MD
A summary of general medicine news that affects your patients, your practice, and you.
By David Boyer, MD
The recommendations on how the academic medical community should conduct relationships with industry will have an impact on ophthalmic practice, leaders say.
By Rachel M. Renshaw, Editor in Chief
By Adam Martidis, MD
By Lawrence Y. Ho, MD; and Chirag P. Shah, MD, MPH
Federal legislative and regulatory policy changes have created an environment in which vitreoretinal surgery should proliferate in the ASC.
By Michael A. Romansky, JD
A new surgical technique for tractional retinal detachment.
By J. Fernando Arevalo, MD, FACS
A revolution or a chimera?
By Stefano Piermarocchi, MD
While this pathway presents potential therapeutic targets, the details of delivery would be challenging.
By Rando Allikmets, PhD
Inheritance patterns of retinal diseases.
By Xining He; Irena Tsui, MD; and Stephen H. Tsang, MD, PhD
Three adult patients with LCA2 show signs of efficacy with no serious adverse effects.
By Albert M. Maguire, MD
Involving patients in their own vision care maintenance requires education and the right tools.
By Robert Lowenthal, MD
For the Photographic Screening For Retinopathy Of Prematurity (Photo-ROP) Cooperative Group*
By Antonio Capone Jr., MD
Looking for small changes with advanced imaging technology and pinpoint diagnosis.
By Michael Bennett, MD
The role of FA and OCT to guide treatment with anti-VEGF therapy in patients with neovascular AMD.
By Christopher B. Chambers, MD; and Tamer H. Mahmoud, MD, PhD
Combined therapies allow globe retention and limited visual preservation.
By Fariba Ghassemi, MD; and Carol L. Shields, MD
The next era of evolution in vitreous cutters will be driven by the quest to increase efficiency, improve safety, expand indications for use, and reduce costs.
By Sophia Y. Fang; Joel M. Cicchella; and Mark S. Humayun, MD, PhD
A Q-switched Nd:YAG laser may allow treatment earlier and closer to the fovea than standard laser photocoagulation.
By John Marshall, PhD, FRCPath, FRCOphth(Hon); Lucia Pelonsis, MRCOphth; Peter Hamilton, FRCS, FRCOphth; and Robin Hamilton, MBBS, MRCOphth
FDA-approved injectable triamcinolone acetonide is formulated for intraocular use.
By Seenu M. Hariprasad, MD; and David S. Dyer, MD
Dr. Bressler is Chief of the Retina Division, Wilmer Eye Institute, and the inagural James P. Gills Professor of Ophthalmology at Johns Hopkins University School of Medicine in Baltimore. He is also Chair of the Data and Safety Monitoring Committee for the National Eye Institute's (NEI's) intramural clinical trials, Chair of both the Submacular Surgery Trials and the Diabetic Retinopathy Clinical Research Network (DRCR.net), and is Chair of the US Food and Drug Administration's Ophthalmic Devices Panel.
By 5 Questions with Neil M. Bressler, MD
Advertisement
Inheritance patterns of retinal diseases.
By Xining He; Irena Tsui, MD; and Stephen H. Tsang, MD, PhD
A Q-switched Nd:YAG laser may allow treatment earlier and closer to the fovea than standard laser photocoagulation.
By John Marshall, PhD, FRCPath, FRCOphth(Hon); Lucia Pelonsis, MRCOphth; Peter Hamilton, FRCS, FRCOphth; and Robin Hamilton, MBBS, MRCOphth
FDA-approved injectable triamcinolone acetonide is formulated for intraocular use.
By Seenu M. Hariprasad, MD; and David S. Dyer, MD
By Lawrence Y. Ho, MD; and Chirag P. Shah, MD, MPH
The role of FA and OCT to guide treatment with anti-VEGF therapy in patients with neovascular AMD.
By Christopher B. Chambers, MD; and Tamer H. Mahmoud, MD, PhD